Sprint Bioscience AB (publ) (SPRINT.ST)
SEK 1.6
(0.25%)
SEK 1.6
(0.25%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 50.48 Million SEK | 60725.3% |
| 2022 | 83 Thousand SEK | -99.76% |
| 2021 | 35.11 Million SEK | 107.96% |
| 2020 | 16.88 Million SEK | -49.66% |
| 2019 | 33.54 Million SEK | 87.0% |
| 2018 | 17.93 Million SEK | -25.16% |
| 2017 | 23.96 Million SEK | -31.51% |
| 2016 | 34.99 Million SEK | 352.88% |
| 2015 | 7.72 Million SEK | 67.61% |
| 2014 | 4.6 Million SEK | 94.43% |
| 2013 | 2.37 Million SEK | 49.28% |
| 2012 | 1.58 Million SEK | -32.92% |
| 2011 | 2.36 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 16.69 Million SEK | -6.56% |
| 2024 Q3 | 14.8 Million SEK | -11.35% |
| 2024 Q1 | 17.87 Million SEK | 64.29% |
| 2023 Q2 | 41 Thousand SEK | 0.0% |
| 2023 Q3 | 39.56 Million SEK | 96402.44% |
| 2023 Q1 | - SEK | -100.0% |
| 2023 Q4 | 10.87 Million SEK | -72.51% |
| 2023 FY | 50.48 Million SEK | 60725.3% |
| 2022 FY | 83 Thousand SEK | -99.76% |
| 2022 Q3 | 5000.00 SEK | -72.22% |
| 2022 Q2 | 18 Thousand SEK | -60.0% |
| 2022 Q4 | 14 Thousand SEK | 180.0% |
| 2022 Q1 | 45 Thousand SEK | -93.84% |
| 2021 FY | 35.11 Million SEK | 107.96% |
| 2021 Q4 | 731 Thousand SEK | -97.87% |
| 2021 Q3 | 34.34 Million SEK | 286133.33% |
| 2021 Q2 | 12 Thousand SEK | -65.71% |
| 2021 Q1 | 35 Thousand SEK | -97.6% |
| 2020 Q1 | 5.36 Million SEK | 2.05% |
| 2020 FY | 16.88 Million SEK | -49.66% |
| 2020 Q4 | 1.45 Million SEK | -71.93% |
| 2020 Q2 | 4.86 Million SEK | -9.3% |
| 2020 Q3 | 5.19 Million SEK | 6.61% |
| 2019 Q3 | 4.39 Million SEK | -77.2% |
| 2019 FY | 33.54 Million SEK | 87.0% |
| 2019 Q4 | 5.26 Million SEK | 19.82% |
| 2019 Q2 | 19.25 Million SEK | 314.8% |
| 2019 Q1 | 4.64 Million SEK | 2552.0% |
| 2018 Q4 | 175 Thousand SEK | -94.58% |
| 2018 FY | 17.93 Million SEK | -25.16% |
| 2018 Q3 | 3.22 Million SEK | 2705.22% |
| 2018 Q2 | 115 Thousand SEK | -99.35% |
| 2018 Q1 | 17.64 Million SEK | 516.78% |
| 2017 Q1 | 9.23 Million SEK | 2.77% |
| 2017 Q2 | 9.43 Million SEK | 2.22% |
| 2017 Q3 | 2.43 Million SEK | -74.19% |
| 2017 Q4 | 2.86 Million SEK | 17.45% |
| 2017 FY | 23.96 Million SEK | -31.51% |
| 2016 Q2 | 14.73 Million SEK | 366.27% |
| 2016 FY | 34.99 Million SEK | 352.88% |
| 2016 Q4 | 8.98 Million SEK | 10.71% |
| 2016 Q3 | 8.11 Million SEK | -44.93% |
| 2016 Q1 | 3.16 Million SEK | -17.53% |
| 2015 FY | 7.72 Million SEK | 67.61% |
| 2015 Q4 | 3.83 Million SEK | -1.63% |
| 2015 Q3 | 3.89 Million SEK | 264.02% |
| 2015 Q2 | 1.07 Million SEK | -37.46% |
| 2015 Q1 | 1.71 Million SEK | -23.37% |
| 2014 Q4 | 2.23 Million SEK | 253.31% |
| 2014 FY | 4.6 Million SEK | 94.43% |
| 2014 Q1 | 745 Thousand SEK | 553.51% |
| 2014 Q2 | 999 Thousand SEK | 34.09% |
| 2014 Q3 | 632 Thousand SEK | -36.74% |
| 2013 Q3 | 231 Thousand SEK | -88.97% |
| 2013 Q2 | 2.09 Million SEK | 0.0% |
| 2013 Q4 | 114 Thousand SEK | -50.65% |
| 2013 FY | 2.37 Million SEK | 49.28% |
| 2013 Q1 | 2.09 Million SEK | 0.0% |
| 2012 FY | 1.58 Million SEK | -32.92% |
| 2011 FY | 2.36 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Alligator Bioscience AB (publ) | 58.1 Million SEK | 13.117% |
| Ziccum AB (publ) | 3.74 Million SEK | -1247.345% |
| Modus Therapeutics Holding AB (publ) | - SEK | -Infinity% |
| BioArctic AB (publ) | 615.99 Million SEK | 91.804% |
| Mendus AB (publ) | 28.48 Million SEK | -77.221% |
| Genovis AB (publ.) | 158.23 Million SEK | 68.094% |
| Intervacc AB (publ) | 8.01 Million SEK | -529.881% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 4.37 Million SEK | -1054.207% |
| Active Biotech AB (publ) | - SEK | -Infinity% |
| Magle Chemoswed Holding AB (publ) | 170.44 Million SEK | 70.38% |
| Bio-Works Technologies AB (publ) | 43.89 Million SEK | -15.01% |
| Aptahem AB (publ) | 2.63 Million SEK | -1819.109% |
| Vicore Pharma Holding AB (publ) | - SEK | -Infinity% |
| Kancera AB (publ) | 1.03 Million SEK | -4777.778% |
| Infant Bacterial Therapeutics AB (publ) | 77 Thousand SEK | -65464.935% |
| Fluicell AB (publ) | 3.33 Million SEK | -1412.433% |
| Saniona AB (publ) | 16.84 Million SEK | -199.792% |
| Lipigon Pharmaceuticals AB (publ) | 16.4 Million SEK | -207.704% |
| Biovica International AB (publ) | 7.29 Million SEK | -592.524% |
| Spago Nanomedical AB (publ) | 1.2 Million SEK | -4096.592% |
| AcouSort AB (publ) | 10.55 Million SEK | -378.485% |
| Xintela AB (publ) | 78 Thousand SEK | -64624.359% |
| Abliva AB (publ) | 137 Thousand SEK | -36750.365% |
| Egetis Therapeutics AB (publ) | 57.6 Million SEK | 12.352% |
| Karolinska Development AB (publ) | 2.01 Million SEK | -2406.703% |
| OncoZenge AB (publ) | 3000.00 SEK | -1682733.333% |
| Amniotics AB (publ) | - SEK | -Infinity% |
| 2cureX AB (publ) | 155 Thousand SEK | -32470.968% |
| CombiGene AB (publ) | 5.54 Million SEK | -810.605% |
| Asarina Pharma AB (publ) | - SEK | -Infinity% |
| Calliditas Therapeutics AB (publ) | 1.2 Billion SEK | 95.817% |
| Camurus AB (publ) | 1.71 Billion SEK | 97.059% |
| Corline Biomedical AB | 25.03 Million SEK | -101.698% |
| IRLAB Therapeutics AB (publ) | 5.67 Million SEK | -789.133% |
| Isofol Medical AB (publ) | 721 Thousand SEK | -6902.08% |
| I-Tech AB | 120.86 Million SEK | 58.229% |
| Hansa Biopharma AB (publ) | 134.09 Million SEK | 62.351% |
| Cyxone AB (publ) | 5.14 Million SEK | -880.672% |
| ExpreS2ion Biotech Holding AB (publ) | 7.05 Million SEK | -616.099% |
| Biosergen AB | - SEK | -Infinity% |
| Cantargia AB (publ) | - SEK | -Infinity% |
| NextCell Pharma AB | 10.66 Million SEK | -373.384% |
| Xspray Pharma AB (publ) | - SEK | -Infinity% |
| Elicera Therapeutics AB (publ) | 11.23 Million SEK | -349.552% |
| Nanologica AB (publ) | 1.44 Million SEK | -3398.614% |
| SynAct Pharma AB | - SEK | -Infinity% |
| Annexin Pharmaceuticals AB (publ) | - SEK | -Infinity% |
| Stayble Therapeutics AB (publ) | - SEK | -Infinity% |
| LIDDS AB (publ) | - SEK | -Infinity% |
| Lipum AB (publ) | 53 Thousand SEK | -95154.717% |
| BioInvent International AB (publ) | 71.46 Million SEK | 29.353% |
| Alzinova AB (publ) | 270 Thousand SEK | -18598.148% |
| Oncopeptides AB (publ) | 35.22 Million SEK | -43.342% |
| Pila Pharma AB (publ) | 1.46 Million SEK | -3350.739% |
| Guard Therapeutics International AB (publ) | - SEK | -Infinity% |
| Scandinavian ChemoTech AB (publ) | 2.82 Million SEK | -1688.979% |
| Simris Alg AB (publ) | 4.35 Million SEK | -1059.508% |
| Diamyd Medical AB (publ) | 130 Thousand SEK | -38734.615% |
| Xbrane Biopharma AB (publ) | 238.72 Million SEK | 78.853% |
| Ascelia Pharma AB (publ) | - SEK | -Infinity% |
| Diagonal Bio AB (publ) | 23 Thousand SEK | -219400.0% |